Physician profile
Cameron S Luo
NPI 1902809478
$7,332.82
in general payments reported to CMS, 2019-2025
59 companies · $1,539 in 2025
The $1,539 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $608 · 2020: $816 · 2021: $1,214 · 2022: $893 · 2023: $1,064 · 2024: $1,198 · 2025: $1,539.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,696 · Education: $105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,695.55 |
| Education | $105.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $711.95 | 2019-2025 | |
| Abbvie INC. | $699.24 | 2021-2025 | |
| Ucb, INC. | $595.83 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Teva Pharmaceuticals USA, INC. | $407.83 | 2020-2025 | Austedo Xr, Austedo Xr |
| Vanda Pharmaceuticals INC. | $344.48 | 2025 | Ponvory |
| Livanova USA, INC. | $297.85 | 2019-2024 | Vns Therapy Sentiva Model 1000 Generator |
| Amneal Pharmaceuticals LLC | $270.72 | 2019-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Neurocrine Biosciences, INC. | $266.96 | 2020-2025 | Ingrezza, Ongentys |
| Novartis Pharmaceuticals Corporation | $265.36 | 2019-2025 | |
| Biogen, INC. | $241.84 | 2019-2025 | Vumerity, Avonex, Tysabri |
| Alexion Pharmaceuticals, INC. | $216.83 | 2019-2025 | Ultomiris |
| Supernus Pharmaceuticals, INC. | $201.52 | 2019-2023 | Oxtellar Xr |
| Amgen INC. | $192.64 | 2019-2022 | |
| Lilly USA, LLC | $170.64 | 2019-2024 | Emgality, Kisunla, Reyvow |
| Argenx US, INC. | $146.85 | 2023-2025 | Vyvgart, Vyvgart Hytrulo |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cameron Luo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.